Filing Flows › Immunome (IMNM) › Q1 2025 › vs Q4 2024
Immunome (IMNM) Q1 2025 vs Q4 2024 (quarter over quarter)
Immunome's revenue rose $188K (+7%) from $2.7M in Q4 2024 to $2.9M in Q1 2025.
Immunome, Q1 2025: revenue $2.9M (+184% year over year), net loss $41.6M, operating cash flow −$53.1M. The chart draws each line against Q4 2024, the increases inside each band.
Every line
| Line | Q1 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $2.9M | $2.7M | $188K | +7% |
| Other income, net | $3.0M | $2.7M | $275K | +10% |
| Net loss | $41.6M | $80.2M | −$38.6M | -48% |
| Costs & expenses | $47.6M | $85.7M | −$38.1M | -45% |
| Operating costs | $47.6M | $85.7M | −$38.1M | -45% |
| Research & development | $36.9M | $47.9M | −$11.0M | -23% |
| General & admin | $10.7M | $10.4M | $244K | +2% |
| Operating cash sources | $59.4M | $48.0M | $11.4M | +24% |
| Depreciation & amortization | $611K | $450K | $161K | +36% |
| Share-based compensation | $5.7M | $5.5M | $233K | +4% |
| Cash used in operations | $53.1M | $42.1M | $11.0M | +26% |
| Net loss absorbed | $41.6M | $80.2M | −$38.6M | -48% |
| Working capital & other | $17.7M | −$32.3M | $50.0M | — |
Questions
How much did Immunome's revenue grow quarter over quarter in Q1 2025?
Immunome's revenue rose $188K (+7%) from $2.7M in Q4 2024 to $2.9M in Q1 2025.